These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17974527)

  • 21. Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance.
    Tokuyasu N; Shomori K; Nishihara K; Kawaguchi H; Fujioka S; Yamaga K; Ikeguchi M; Ito H
    Gastric Cancer; 2008; 11(1):37-46. PubMed ID: 18373176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological prognostic factors for early stage completely resected non-small cell lung cancer.
    Cagini L; Monacelli M; Giustozzi G; Moggi L; Bellezza G; Sidoni A; Bucciarelli E; Darwish S; Ludovini V; Pistola L; Gregorc V; Tonato M
    J Surg Oncol; 2000 May; 74(1):53-60. PubMed ID: 10861611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
    Pilka R; Mícková I; Lubuský M; Dusková M; Rícánková M; Kudela M
    Ceska Gynekol; 2008 Jul; 73(4):222-7. PubMed ID: 18711961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors.
    Menezes HL; Jucá MJ; Gomes EG; Nunes BL; Costa HO; Matos D
    Arq Gastroenterol; 2010; 47(2):141-7. PubMed ID: 20721457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of cell proliferation markers and p53 mutation status on prognosis of non-metastatic colon cancer.
    Demir L; Ekinci N; Erten C; Somali I; Can A; Dirican A; Cokmert S; Bayoglu V; Akyol M; Kucukzeybek Y; Alacacioglu A; Tarhan MO
    J Surg Oncol; 2014 Jun; 109(7):665-75. PubMed ID: 24464927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma.
    Couture C; Raybaud-Diogène H; Têtu B; Bairati I; Murry D; Allard J; Fortin A
    Cancer; 2002 Feb; 94(3):713-22. PubMed ID: 11857304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cdc2 as prognostic marker in stage UICC II colon carcinomas.
    Meyer A; Merkel S; Brückl W; Schellerer V; Schildberg C; Campean V; Hohenberger W; Croner RS
    Eur J Cancer; 2009 May; 45(8):1466-73. PubMed ID: 19223178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy.
    Grabenbauer GG; Mühlfriedel C; Rödel F; Niedobitek G; Hornung J; Rödel C; Martus P; Iro H; Kirchner T; Steininger H; Sauer R; Weidenbecher M; Distel L
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1041-50. PubMed ID: 11072161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease.
    Shiohara S; Shiozawa T; Miyamoto T; Feng YZ; Kashima H; Kurai M; Suzuki A; Konishi I
    Virchows Arch; 2005 Jun; 446(6):626-33. PubMed ID: 15891905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
    Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
    Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined analysis of biomarkers of proliferation and apoptosis in colon cancer: an immunohistochemistry-based study using tissue microarray.
    Reimers MS; Zeestraten EC; van Alphen TC; Dekker JW; Putter H; Saadatmand S; Liefers GJ; van de Velde CJ; Kuppen PJ
    Int J Colorectal Dis; 2014 Sep; 29(9):1043-52. PubMed ID: 24950792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence.
    Sawair F; Hassona Y; Irwin C; Stephenson M; Hamilton P; Maxwell P; Gordon D; Leonard A; Napier S
    Asian Pac J Cancer Prev; 2016; 17(3):1243-9. PubMed ID: 27039754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study.
    Raybaud-Diogène H; Fortin A; Morency R; Roy J; Monteil RA; Têtu B
    J Clin Oncol; 1997 Mar; 15(3):1030-8. PubMed ID: 9060543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
    Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histopathological analysis of apoptosis, and expression of p53, bcl-2, bax, and Ki-67 in laryngeal squamous cell carcinomas and dysplasia.
    Izawa H; Yonemitsu N; Shin T; Sugihara H
    Auris Nasus Larynx; 1999 Jul; 26(3):317-30. PubMed ID: 10419041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.